Compare Upstart Holdings Inc (UPST) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Upstart Holdings Inc vs GeneDx Holdings Corp — how do they compare? Upstart Holdings Inc trades at $26.07 (market cap $2.63B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.56B). The key difference: Upstart Holdings Inc and GeneDx Holdings Corp are close in size by market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Upstart Holdings Inc nearer its low. Which is the better fit depends on your goals.
| UPST | WGS | |
|---|---|---|
Market Cap | $2.63B | $2.56B |
Sector | Financials | Technology |
52-Week High | $68.11 | $167.51 |
52-Week Low | $24.22 | $34.51 |
Enterprise Value | — | $2.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Upstart Holdings (UPST) trades at $26.98, down 3.81% on the day, reflecting bearish technical momentum and recent earnings misses. The stock shows oversold conditions with an RSI of 18.98, while fundamentals indicate a turnaround with 2025 net income of $53.60M on $1.02B revenue, marking its first annual profit. Analyst sentiment is mixed with a 45.46% buy rating and $47.20 consensus target, but insider selling and weak cash flow from operations pose concerns.
The outlook hinges on execution in personal loan growth and AI lending efficiency, but risks include high debt-to-asset ratio of 61.48% and macroeconomic sensitivity. Near-term resistance at $28 challenges upside, while support at $26 may stabilize declines if earnings improve in Q3 2026.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
